基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抑制剂 帕米帕利 帕米帕里布(BGB-290)
  • aladdin 阿拉丁 P414075 帕米帕里布(BGB-290) 1446261-44-4 99%

aladdin 阿拉丁 P414075 帕米帕里布(BGB-290) 1446261-44-4 99%

Pamiparib (BGB-290)
1446261-44-4
556.90 2mg 起订
793.90 5mg 起订
2780.90 25mg 起订
上海 更新日期:2025-05-16

上海阿拉丁生化科技股份有限公司

VIP2年
联系人:阿拉丁客服
电话:400-6206333拨打
手机:13167063860 拨打
邮箱:anhua.mao@aladdin-e.com

产品详情:

中文名称:
帕米帕里布(BGB-290)
英文名称:
Pamiparib (BGB-290)
CAS号:
1446261-44-4
品牌:
阿拉丁
产地:
上海
保存条件:
-20°C储存
纯度规格:
Moligand™, ≥99%
产品类别:
小分子和化合物库 配体家族
分子式:
C16H15FN4O
分子量:
298.31
运输条件:
超低温运输
产品规格:
25mg、2mg、5mg
货号:
P414075
是否进口:

中文名:帕米帕里布(BGB-290)

英文名:Pamiparib (BGB-290)

纯度:Moligand™,≥99%

货号:P414075

Cas号:1446261-44-4

存储温度:-20°C储存

运输条件:超低温运输

产品介绍:

Information

Pamiparib (BGB-290) is a potent and selective inhibitor ofPARP1andPARP2with IC50 values of 0.83 and 0.11 nM, respectively in biochemical assays. It shows high selectivity over other PARP enzymes.


Targets

PARP2 (Cell-free assay); PARP1 (Cell-free assay) 0.11 nM; 0.83 nM


In vitro

BGB-290 shows potent DNA-trapping activity with IC50 of 13 nM. In the cellular assays, BGB-290 inhibits intracellular PAR formation with an IC50 of 0.24 nM.


In vivo

Oral administration of BGB-290 results in time-dependent and dose-dependent inhibition of PARylation in MDA-MB-436 (BRCA1 mutant) breast cancer xenograft, correlating well with the tumor drug concentrations. BGB-290 has also demonstrated good combination activity with chemotherapeutics in patient biopsy derived SCLC models. BGB-290 has significant brain penetration in C57 mice. The drug exposure in brain vs. that in plasma was close to 20% after oral administration of BGB-290.


Product Application:

Pamiparib, an investigational Poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development, demonstrates excellent selectivity for both PARP1 and PARP2, and superb anti-proliferation activities in tumor cell lines with BRCA1/2 mutations or HR pathway deficiency (HRD). Pamiparib has good bioavailability and is 16-fold more potent than olaparib in an efficacy study using BRCA1 mutated MDA-MB-436 breast cancer xenograft model. Pamiparib also shows strong anti-tumor synergy with temozolomide (TMZ), a DNA alkylating agent used to treat brain tumors. Compared to other PARP inhibitors, pamiparib demonstrated improved penetration across the blood brain barrier (BBB) in mice. Oral administration of pamiparib at a dose as low as 3 mg/kg is sufficient to abrogate PARylation in brain tumor tissues. In SCLC-derived, TMZ-resistant H209 intracranial xenograft model, combination of pamiparib with TMZ overcomes its resistance and shows significant tumor inhibitory effects and prolonged life span.


查看阿拉丁官网此产品相关对应页面:https://www.aladdin-e.com/zh_cn/P414075.html


(10aR)-2-Fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta(1,2,3,4-def)cyclopenta(a)fluoren-4(7H)-one ; A884779 ; Pamiparib [INN] ; BP180190

公司简介

上海阿拉丁生化科技股份有限公司是A股上市公司((股票代码:688179),专注于科研试剂的研发、生产和销售,已陆续建立多个工厂和研发中心。作为领军企业,阿拉丁始终坚持质量第一,连续13年被评为“最受欢迎试剂品牌”。 阿拉丁目前常备库存试剂产品品种超过7万种,SKU总数超过46万,产品线涵盖了化学试剂、生化试剂、药靶配体、蛋白质和抗体等多个领域,是国内少数化学试剂到生物试剂全面发展的国产试剂品牌,产品同步发布在我们国内外电商平台。

成立日期 (17年)
注册资本 14130.676万人民币
员工人数 500人以上
年营业额 ¥ 1亿以上
经营模式 工厂,试剂
主营行业 生物化工,化学试剂

帕米帕里布(BGB-290)相关厂家报价 更多

  • BGB290
  • BGB290
  • 深圳盛大医药科技有限公司
  • 2023-03-15
  • 询价
内容声明
拨打电话 立即询价